Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 268-274

  Shirts, Brian H ^a,b   Prasad, Konasale M ^a   Pogue Geile, Michael F ^a   Dickerson, Faith ^c   Yolken, Robert H ^d   Nimgaonkar, Vishwajit L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c SHEPPARD PRATT HEALTH SYSTEM   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; Cognitive impairment; Cytomegalovirus; Environmental etiology; Herpes Simplex Virus; Schizophrenia; Trail Making Test; Working memory

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; HERPES SIMPLEX VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ARTICLE; COGNITION; COGNITIVE DEFECT; CYTOMEGALOVIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR PERFORMANCE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEROLOGY; TOXOPLASMA GONDII; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; COGNITION DISORDERS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TOXOPLASMA; TRAIL MAKING TEST;

EID: 56149109020     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.07.017     Document Type: Article

References (54)

1. Aiello A.E., Haan M., Blythe L., Moore K., Gonzalez J.M., and Jagust W. The influence of latent viral infection on rate of cognitive decline over 4 years. J. Am. Geriatr. Soc. 54 7 (2006) 1046-1054
2. A.P.A. Diagnostic and Statistical Manual of Mental Disorders - DSM-IV (1994)
3. Arbuthnott K., and Frank J. Trail Making Test, part B as a measure of executive control: validation using a set-switching paradigm. J. Clin. Exp. Neuropsychol. 22 4 (2000) 518-528
4. Army Individual Test Battery. Manual of Directions and Scoring (1944), War Department, Adjuntant General's Office, Washington D.C.
5. Ashley R.L., Wu L., Pickering J.W., Tu M.C., and Schnorenberg L. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for Herpes Simplex Virus type-specific antibodies. J. Clin. Microbiol. 36 1 (1998) 294-295
6. Barch D.M., Carter C.S., Braver T.S., Sabb F.W., MacDonald III A., Noll D.C., and Cohen J.D. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 58 3 (2001) 280-288
7. Brown A.S., Cohen P., Harkavy-Friedman J., Babulas V., Malaspina D., Gorman J.M., and Susser E.S. A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol. Psychiatry 49 6 (2001) 473-486
8. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., Babulas V.P., and Susser E.S. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Obstet. Gynecol. Surv. 60 2 (2005) 77-78
9. Brown A.S., Schaefer C.A., Quesenberry Jr. C.P., Liu L., Babulas V.P., and Susser E.S. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 162 4 (2005) 767-773
10. Callicott J.H., Mattay V.S., Verchinski B.A., Marenco S., Egan M.F., and Weinberger D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 160 12 (2003) 2209-2215
11. Chowdari K.V., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., Deshpande S.N., Thelma B.K., Ferrell R.E., Middleton F.A., Devlin B., Levitt P., Lewis D.A., and Nimgaonkar V.L. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mol. Genet. 11 12 (2002) 1373-1380
12. Cleator G.M., and Klapper P.E. In: Zuckerman A.J., Banatvala J.E., and Pattison J.R. (Eds). Herpes Simplex. Principles and Practice of Clinical Virology (2004), John Wiley and Sons, Ltd, New York 27-51
13. Crowe S.F. The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on parts A and B of the Trail Making Test. J. Clin. Psychol. 54 5 (1998) 585-591
14. Dalman C., Allebeck P., Gunnell D., Harrison G., Kristensson K., Lewis G., Lofving S., Rasmussen F., Wicks S., and Karlsson H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry 165 1 (2008) 59-65
15. Demakis G.J. Frontal lobe damage and tests of executive processing: a meta-analysis of the category test, Stroop test, and trail-making test. J. Clin. Exp. Neuropsychol. 26 3 (2004) 441-450
16. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., and Yolken R.H. Association of serum antibodies to Herpes Simplex Virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 60 5 (2003) 466-472
17. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Cole S., Krivogorsky B., and Yolken R.H. Infection with Herpes Simplex Virus type 1 is associated with cognitive deficits in bipolar disorder. Biol. Psychiatry 55 6 (2004) 588-593
18. Dickerson F., Stallings C., Origoni A., Boronow J., and Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 93 1-3 (2007) 261-265
19. Dickerson, F., Stallings, C., Sullens, A., Origoni, A., Leister, F., Krivogorsky, B., Yolken, R., in press. Association between cognitive functioning, exposure to Herpes Simplex Virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. Brain Behav. Immun. (Electronic publication ahead of print).
20. Drane D.L., Yuspeh R.L., Huthwaite J.S., and Klingler L.K. Demographic characteristics and normative observations for derived-Trail Making Test indices. Neuropsychiatry Neuropsychol. Behav. Neurol. 15 1 (2002) 39-43
21. Endicott J., Spitzer R., Fleiss J., and Cohen J. The global assessment scale. Arch. Gen. Psychiatry 33 (1976) 766-771
22. Eyler Zorrilla L.T., Heaton R.K., McAdams L.A., Zisook S., Harris M.J., and Jeste D.V. Cross-sectional study of older outpatients with schizophrenia and healthy comparison subjects: no differences in age-related cognitive decline. Am. J. Psychiatry 157 8 (2000) 1324-1326
23. Gray J.A., and Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 33 5 (2007) 1100-1119
24. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 26 1 (2000) 119-136
25. Hanshaw J.B. In: Remington J.S., and Kelin J.O. (Eds). Cytomegalovirus. Infectious Diseases of the Fetus and Newborn Infant (1976), Saunders, Philadelphia (PA) 127
26. Heaton R., Paulsen J.S., McAdams L.A., Kuck J., Zisook S., Braff D., Harris J., and Jeste D.V. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch. Gen. Psychiatry 51 6 (1994) 469-476
27. Hyde T.M., Nawroz S., Goldberg T.E., Bigelow L.B., Strong D., Ostrem J.L., Weinberger D.R., and Kleinman J.E. Is there cognitive decline in schizophrenia? A cross-sectional study. Br. J. Psychiatry 164 4 (1994) 494-500
28. Keefe R.S., and Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 33 4 (2007) 912-920
29. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19 2 (1993) 355-370
30. Koponen H., Rantakallio P., Veijola J., Jones P., Jokelainen J., and Isohanni M. Childhood central nervous system infections and risk for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254 1 (2004) 9-13
31. Leonard B.E. Inflammation, depression and dementia: are they connected?. Neurochem. Res. 32 10 (2007) 1749-1756
32. Leweke F.M., Gerth C.W., Koethe D., Klosterkotter J., Ruslanova I., Krivogorsky B., Torrey E.F., and Yolken R.H. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254 1 (2004) 4-8
33. Mahurin R.K., Velligan D.I., Hazleton B., Mark Davis J., Eckert S., and Miller A.L. Trail Making Test errors and executive function in schizophrenia and depression. Clin. Neuropsychol. 20 2 (2006) 271-288
34. Marshall G.S., and Stout G.G. Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period. Am. J. Perinatol. 22 7 (2005) 371-376
35. McGurk S.R., Twamley E.W., Sitzer D.I., McHugo G.J., and Mueser K.T. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 164 12 (2007) 1791-1802
36. Nayak Savla G., Moore D.J., Roesch S.C., Heaton R.K., Jeste D.V., and Palmer B.W. An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophr. Res. 83 2-3 (2006) 215-223
37. Niebuhr D.W., Millikan A.M., Cowan D.N., Yolken R., Li Y., and Weber N.S. Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am. J. Psychiatry 165 1 (2008) 99-106
38. O'Donnell B.F. Cognitive impairment in schizophrenia: a life span perspective. Am. J. Alzheimer's Dis. Other Dement. 22 5 (2007) 398-405
39. Pearce B.D. Can a Virus Cause Schizophrenia?: Facts and Hypotheses (2003), Kluwer Academic, Boston
40. Perianez J.A., Rios-Lago M., Rodriguez-Sanchez J.M., Adrover-Roig D., Sanchez-Cubillo I., Crespo-Facorro B., Quemada J.I., and Barcelo F. Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: sample comparisons and normative data. Arch. Clin. Neuropsychol. 22 4 (2007) 433-447
41. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., and Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63 8 (2008) 801-808
42. Prasad K.M., Shirts B.H., Yolken R.H., Keshavan M.S., and Nimgaonkar V.L. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol. Psychiatry 12 1 (2007) 105-113
43. Rantakallio P., Jones P., Moring J., and Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up. Int. J. Epidemiol. 26 4 (1997) 837-843
44. Shibuya-Tayoshi S., Sumitani S., Kikuchi K., Tanaka T., Tayoshi S., Ueno S., and Ohmori T. Activation of the prefrontal cortex during the Trail-Making Test detected with multichannel near-infrared spectroscopy. Psychiatry Clin. Neurosci. 61 6 (2007) 616-621
45. Shirts B.H., Kim J.J., Reich S., Dickerson F.B., Yolken R.H., Devlin B., and Nimgaonkar V.L. Polymorphisms in MICB are associated with human herpes virus seropositivity and schizophrenia risk. Schizophr. Res. 94 1-3 (2007) 342-353
46. Shirts B.H., Wood J., Yolken R.H., and Nimgaonkar V.L. Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 18 (2007) 18
47. SPSS. Statistical Package for Social Sciences (2005) SPSS, Inc., Chicago, Illinois
48. Strandberg T.E., Pitkala K.H., Linnavuori K.H., and Tilvis R.S. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke 34 9 (2003) 2126-2131
49. Stuss D.T., Bisschop S.M., Alexander M.P., Levine B., Katz D., and Izukawa D. The Trail Making Test: a study in focal lesion patients. Psychol. Assess. 13 2 (2001) 230-239
50. Talkowski M.E., Kirov G., Bamne M., Georgieva L., Torres G., Mansour H., Chowdari K.V., Milanova V., Wood J., McClain L., Prasad K., Shirts B., Zhang J., O'Donovan M.C., Owen M.J., Devlin B., and Nimgaonkar V.L. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum. Mol. Genet. 17 5 (2008) 747-758
51. Torrey E.F., and Yolken R.H. Toxoplasma gondii and schizophrenia. Emerg. Infect. Dis. 9 11 (2003) 1375-1380
52. Wang H.L., Wang G.H., Li Q.Y., Shu C., Jiang M.S., and Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr. Scand. 114 1 (2006) 40-48
53. Wood S.J., Brewer W.J., Koutsouradis P., Phillips L.J., Francey S.M., Proffitt T.M., Yung A.R., Jackson H.J., McGorry P.D., and Pantelis C. Cognitive decline following psychosis onset: data from the PACE clinic. Br. J. Psychiatry Suppl. 51 7 (2007) s52--s7
54. Yolken R. Viruses and schizophrenia: a focus on Herpes Simplex Virus. Herpes 11 2 (2004) 83A-88A